- Home
- JFU vs INKT Comparison
JFU vs INKT Comparison
Compare JFU & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JFU | INKT |
|---|---|---|
| Founded | 2006 | 2017 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 54.5M | 57.6M |
| IPO Year | 2018 | 2021 |
Fundamental Metrics
Financial Performance| Metric | JFU | INKT |
|---|---|---|
| Price | $4.35 | $9.85 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $35.00 |
| AVG Volume (30 Days) | 2.6K | ★ 141.0K |
| Earning Date | 01-01-0001 | 03-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $1.43 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.01 | $6.66 |
| 52 Week High | $9.48 | $76.00 |
Technical Indicators
Market Signals| Indicator | JFU | INKT |
|---|---|---|
| Relative Strength Index (RSI) | 43.31 | 42.47 |
| Support Level | $4.24 | $6.80 |
| Resistance Level | $5.66 | $12.97 |
| Average True Range (ATR) | 0.28 | 0.58 |
| MACD | 0.05 | -0.04 |
| Stochastic Oscillator | 9.79 | 9.36 |
Price Performance
Historical ComparisonAbout JFU 9F Inc.
9F Inc is a financial account platform integrating and personalizing financial services in China. It provides a range of financial products and services across online lending, wealth management, and payment facilitation, all integrated under a single digital financial account. The company's operations are organized into Material segments, consisting of E-commerce services, technology Empowerment service and Wealth Management services, of which it derives maximum revenue from technology Empowerment service. All its revenues are generated from the People's Republic of China.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.